Prof. Ioannis Zervantonakis' research integrates microfluidics, systems biology, and in vivo models to study cancer metastasis, drug resistance, and tumor microenvironment interactions in cancers. His lab develops synthetic biology tools such as microfluidic assays to model tumor-immune interactions, investigates single-cell phenotypic decisions, and explores localized drug delivery strategies. Their long-term goal is to identify biomarkers for improved therapies and personalized cancer treatments.
"Paracrine Ovarian Cancer Cell-Derived CSF1 Signaling Regulates Macrophage Migration Dynamics in a 3D Microfluidic Model that Recapitulates In Vivo Infiltration Patterns in Patient-Derived Xenografts"
Scott AL, Jazwinska DE, Kulawiec DG, Zervantonakis IK. Adv Healthc Mater. 2024, 13, 28, e2401719
"Fabrication of 3D-printed molds for polydimethylsiloxane-based microfluidic devices using a liquid crystal display-based vat photopolymerization process: printing quality, drug response and 3D invasion cell culture assays"
Poskus MD, Wang T, Deng Y, Borcherding S, Atkinson J, Zervantonakis IK. Microsyst Nanoeng. 2023, 9, 140
"Beyond matrix stiffness: targeting force-induced cancer drug resistance"
Kalli M, Poskus MD, Stylianopoulos T, Zervantonakis IK. Trends Cancer. 2023, 9, 11, 937-954
"Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment"
Jazwinska DE, Kulawiec DG, Zervantonakis IK. Am J Physiol Cell Physiol. 2023, 325, 3, C721-C730
"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer"
Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Nat Rev Cancer. 2022, 26, 6, 323-339